GLOW Protocol research

The GLOW Protocol evidence base cited here is 4 sources — 2 review. Regulatory status: Not FDA-approved (blend).

• GLOW is a marketed COMBINATION (blend), not a single peptide: a fixed ratio of BPC-157, TB-500, and GHK-Cu sold for skin rejuvenation and tissue repair.
• Its effects come from the individual components — BPC-157 (anti-inflammatory/repair), TB-500 (angiogenesis), GHK-Cu (collagen/elastin) — and there is little formal research on the fixed-ratio blend itself.
• None of the components is FDA-approved; the strongest component evidence (GHK-Cu skin effects) is largely topical, and BPC-157/TB-500 data is overwhelmingly preclinical.

GLOW's rationale is that three complementary regenerative pathways — anti-inflammation/repair (BPC-157), angiogenesis (TB-500), and matrix synthesis (GHK-Cu) — together support skin and tissue. Important caveat the product category itself flags: this is a convenience combination, and there is little evidence the fixed ratio is synergistic rather than simply additive. Treat the mechanism as 'three known peptides at once', not a novel mechanism.

None of GLOW's components is FDA-approved; the blend is sold for laboratory research only and is not intended for human consumption. BPC-157 in particular is on the WADA Prohibited List (2022) — relevant for tested athletes.

All citations link to the original source (PubMed, journal site, or regulatory filing). Independent research database — no vendor influence on what's cited.